TickerFacts.

Compare

HUTCHMED (China) Ltd vs Organogenesis Holdings Inc. vs Mirum Pharmaceuticals, Inc. vs BridgeBio Pharma, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearHUTCHMED (China) Ltd
HCM		Organogenesis Holdings Inc.
ORGO		Mirum Pharmaceuticals, Inc.
MIRM		BridgeBio Pharma, Inc.
BBIO
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$548.51M$564.17M$521.31M$502.08M
Revenue growth (YoY)-13.0%+17.0%+54.7%+126.3%
Gross margin38.7% (computed)n/an/an/a
Operating margin-7.1%7.9%-4.2%-104.2%
Net margin83.3%6.6%-4.5%-146.0%
Net income$456.91M$37.03M-$23.36M-$732.94M
EPS (Diluted)$0.52$0.15-$0.47-$3.78
Operating cash flow-$64.66M-$10.31M$55.83M-$445.91M
Free cash flow-$78.81M-$24.46M$54.87M-$447.01M
Cash & equivalents$71.33M$93.68M$296.68M$570.12M
Total assets$1.75B$598.73M$842.81M$936.02M
Total liabilities$501.83M$164.81M$528.12M$3.01B
Shareholders' equity$1.25B$300.13M$314.69M-$2.09B
Return on year-end equity36.5%12.3%-7.4%n/a
Shares outstandingn/a126.95M51.90M194.77M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearHUTCHMED (China) LtdOrganogenesis Holdings Inc.Mirum Pharmaceuticals, Inc.BridgeBio Pharma, Inc.
Latest$548.51M
Ended 2025-12-31		$564.17M
Ended 2025-12-31		$521.31M
Ended 2025-12-31		$502.08M
Ended 2025-12-31
1 year earlier$630.20M
Ended 2024-12-31		$482.04M
Ended 2024-12-31		$336.89M
Ended 2024-12-31		$221.90M
Ended 2024-12-31
2 years earlier$838.00M
Ended 2023-12-31		$433.14M
Ended 2023-12-31		$186.37M
Ended 2023-12-31		$9.30M
Ended 2023-12-31
3 years earlier$426.41M
Ended 2022-12-31		$450.89M
Ended 2022-12-31		$77.06M
Ended 2022-12-31		$77.65M
Ended 2022-12-31
4 years earlier$356.13M
Ended 2021-12-31		$467.36M
Ended 2021-12-31		$19.14M
Ended 2021-12-31		$69.72M
Ended 2021-12-31